期刊
RSC MEDICINAL CHEMISTRY
卷 12, 期 1, 页码 129-136出版社
ROYAL SOC CHEMISTRY
DOI: 10.1039/d0md00292e
关键词
-
资金
- AbbVie
- Bayer Pharma AG
- Boehringer Ingelheim
- Canada Foundation for Innovation
- Eshelman Institute for Innovation
- Genome Canada
- Genentech
- Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD] [115766]
- Janssen
- Merck KGaA Darmstadt Germany
- MSD
- Novartis Pharma AG
- Ontario Ministry of Economic Development and Innovation
- Pfizer
- Sao Paulo Research Foundation-FAPESP
- Takeda
- Wellcome [106169/ZZ14/Z]
- NC Biotechnology Center Institutional Support Grant [2018-IDG-1030]
- NIH [1U24DK11604]
- American Foundation for Pharmaceutical Education (AFPE) Foundation (RAMSES) [20-0328]
- Spanish MECD [FPU 14/00818]
The study describes a synthesis method for preparing compounds with improved cellular activity while maintaining selectivity for RIOK2. Although these compounds are not RIOK2 chemical probes, they serve as the best tool molecules to begin characterizing RIOK2 function in vitro.
RIOK2 is an understudied kinase associated with a variety of human cancers including non-small cell lung cancer and glioblastoma. No potent, selective, and cell-active chemical probe currently exists for RIOK2. Such a reagent would expedite re-search into the biological functions of RIOK2 and validate it as a therapeutic target. Herein, we describe the synthesis of naphthyl-pyridine based compounds that have improved cellular activity while maintaining selectivity for RIOK2. While our compounds do not represent RIOK2 chemical probes, they are the best available tool molecules to begin to characterize RIOK2 function in vitro.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据